Sign in or Register   Sign in or Register
  |  

Mouse Anti-BRAF Recombinant Antibody (CBYY-0748) (CBMAB-0751-YY)

This product is mouse antibody that recognizes BRAF. The antibody CBYY-0748 can be used for immunoassay techniques such as: IF, IHC, WB
See all BRAF antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-0748
Antibody Isotype
IgG2b
Application
IF, IHC, WB

Basic Information

Immunogen
BRAF antibody was raised in mouse using a full length recombinant protein of human BRAF (NP_004324) produced in HEK293T cells, as the immunogen
Specificity
Human
Antibody Isotype
IgG2b
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
0.5 mg-1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
B-Raf Proto-Oncogene, Serine/Threonine Kinase
Introduction
This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome.
Entrez Gene ID
UniProt ID
Alternative Names
B-Raf Proto-Oncogene, Serine/Threonine Kinase; V-Raf Murine Sarcoma Viral Oncogene Homolog B1; V-Raf Murine Sarcoma Viral Oncogene Homolog B; Proto-Oncogene B-Raf; BRAF1; RAFB1; B-Raf Proto-Oncogene Serine/Threonine-Protein Kinase (P94); Murine Sarcoma Viral (V-Raf) Oncogene Homolog B1; Serine/Threonine-Protein Kinase B-Raf;
Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126).
May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179).
Biological Process
Activation of MAPKK activity Source: UniProtKB
Animal organ morphogenesis Source: ProtInc
Cellular response to calcium ion Source: BHF-UCL
Epidermal growth factor receptor signaling pathway Source: BHF-UCL
Establishment of protein localization to membrane Source: CACAO
MAPK cascade Source: BHF-UCL
Negative regulation of apoptotic process Source: UniProtKB
Positive regulation of ERK1 and ERK2 cascade Source: BHF-UCL
Positive regulation of gene expression Source: BHF-UCL
Positive regulation of glucose transmembrane transport Source: CACAO
Positive regulation of peptidyl-serine phosphorylation Source: UniProtKB
Protein phosphorylation Source: BHF-UCL
Trehalose metabolism in response to stress Source: SGD
Cellular Location
Nucleus; Cell membrane; Cytoplasm. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.
Involvement in disease
Colorectal cancer (CRC): A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Lung cancer (LNCR): A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
Familial non-Hodgkin lymphoma (NHL): Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
Cardiofaciocutaneous syndrome 1 (CFC1): A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices.
Noonan syndrome 7 (NS7): A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.
LEOPARD syndrome 3 (LPRD3): A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.
PTM
Phosphorylation at Ser-365 by SGK1 inhibits its activity.
Methylation at Arg-671 decreases stability and kinase activity.
Ubiquitinated by RNF149; which leads to proteasomal degradation. Polyubiquitinated at Lys-578 in response to EGF.

Ibrahiem, A. T., Fawzy, M. S., Abu AlSel, B. T., & Toraih, E. A. (2021). Prognostic value of BRAF/MIR‐17 signature and B‐Raf protein expression in patients with colorectal cancer: A pilot study. Journal of clinical laboratory analysis, 35(3), e23679.

Chao, A., Huang, Y. L., Lin, C. Y., Chao, A. S., Lee, Y. S., Wu, R. C., & Lai, C. H. (2021). A Case of Paratubal Serous Borderline Tumor Driven by a Somatic BRAF Mutation in an Adolescent Patient. Journal of Pediatric and Adolescent Gynecology, 34(2), 228-230.

Maeda, T., Konishi, H., Takaki, W., Takabatake, K., Matsubara, D., Shoda, K., ... & Otsuji, E. (2021). Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status. Anticancer Research, 41(4), 1761-1769.

González-González, R., López-Verdín, S., Lavalle-Carrasco, J., Molina-Frechero, N., Isiordia-Espinoza, M., Carreón-Burciaga, R. G., & Bologna-Molina, R. (2020). Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: systematic review. World journal of clinical oncology, 11(1), 31.

Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes, 11(11), 1342.

Jiang, G., Zhang, M., Tan, Q., Lin, S., Zeng, Y., Liu, C., ... & Zhou, J. (2019). Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: a case report. Lung Cancer, 137, 52-55.

Hosseini, S., Saidijam, M., Eslami, H., Soltanian, A. R., Mousavi-Bahar, S. H., & Mahdavinezhad, A. (2019). Clinical Significance of BRAF and ZEB2 Expressions in Healthy Adjacent Tissue of Bladder Cancer. Middle East Journal of Cancer, 10(2), 87-94.

Loo, E., Khalili, P., Beuhler, K., Siddiqi, I., & Vasef, M. A. (2018). BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry. Applied immunohistochemistry & molecular morphology, 26(10), 709-713.

Kiuru, M., Tartar, D. M., Qi, L., Chen, D., Yu, L., Konia, T., ... & Fung, M. A. (2018). Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features. Journal of the American Academy of Dermatology, 79(2), 221-229.

Lv, X., Wang, D., Ma, Y., & Long, Z. (2018). Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis. International journal of molecular medicine, 41(3), 1349-1356.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-BRAF Recombinant Antibody (CBYY-0748)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare